Pliant Therapeutics Q1 net loss $37.5M; cash $577M; positive IPF 24-wk data

PLIANT THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.67 revenue$1,332,000

Q1 net loss $37.5M vs $28.1M YoY; R&D expense $29.3M, G&A $14.2M.
Cash and short-term investments $577.3M, expected to fund operations into H2 2026.
INTEGRIS-IPF 320 mg 24-week data: bexotegrast well-tolerated with durable FVC, QLF, and cough improvements.
Key 2023 milestones: INTEGRIS-PSC 12-wk data Q3; BEACON-IPF Ph2b start mid-2023; Ph1 oncology trial start Q2.
Closed Jan 2023 public offering raising $269.9M net proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income Net loss of $37.5 million.

Period: the first quarter ended March 31, 2023
Net income: Net loss of $37.5 million
Result: reported results

Exact text from the filing

On May 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.